SCHEMBL22959705

SCHEMBL22959705

CCC(C)(C)OC1CCN(C(C)(C)C)C1

nearest known ligand 0.34

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11223839 0.84 ATM (0.42) ATM
SCHEMBL16451090 0.80 ATM (0.38) ATM
SCHEMBL9611078 0.80 ATM (0.38) ATM
SCHEMBL16451085 0.80 ATM (0.38) ATM
SCHEMBL25669915 0.79 ALDH1A1 (0.34)
SCHEMBL22930451 0.77 CHRM3 (0.36)
SCHEMBL22652443 0.77 ATM (0.36) ATM
SCHEMBL22652325 0.77 ATM (0.36) ATM
SCHEMBL19497556 0.77 ATM (0.36) ATM
SCHEMBL21579250 0.75 CHRM3 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210038599-A1 SMALL MOLECULE DEGRADERS OF POLYBROMO-1 (PBRM1) DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210038599-A1 SMALL MOLECULE DEGRADERS OF POLYBROMO-1 (PBRM1) PBRM1, SMARCC1, SMARCC2 ATM 1521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.